A randomized, open-label, two arm trial to compare the safety and antiviral efficacy of GW433908 [fosamprenavir]/ritonavir QD [daily] to nelfinavir BID [twice daily] when used in combination with abacavir and lamivudine for 48 weeks in antiretroviral therapy naive HIV-1 infected subjects.

Trial Profile

A randomized, open-label, two arm trial to compare the safety and antiviral efficacy of GW433908 [fosamprenavir]/ritonavir QD [daily] to nelfinavir BID [twice daily] when used in combination with abacavir and lamivudine for 48 weeks in antiretroviral therapy naive HIV-1 infected subjects.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2005

At a glance

  • Drugs Fosamprenavir; Lamivudine/abacavir; Nelfinavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top